跳至主要内容
临床试验/NCT07423481
NCT07423481尚未招募不适用

SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France

Nantes University Hospital1 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2026年10月1日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
3,000
试验地点
1
主要终点
Describe weight changes during the follow-up period according to patient characteristics.

研究概览

简要总结

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
  • No objection to the use of their data
  • Patients able to complete an online questionnaire (via the internet)

排除标准

  • Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection

研究组 & 干预措施

SEMAFOLLOW study population

Patient agreeing to participate in the SEMAFOLLOW study.

干预措施: SEMAFOLLOW questionnaire (Other)

结局指标

主要结局

Describe weight changes during the follow-up period according to patient characteristics.

时间窗: 30 min

次要结局

  • Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.(30 min)
  • Compare the profiles of responders and non-responders(30 min)
  • Describe weight change according to different subpopulations.(30 min)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验